A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway

被引:38
作者
Lazarus, DD
Destree, AT
Mazzola, LM
McCormack, TA
Dick, LR
Xu, B
Huang, JQ
Pierce, JW
Read, MA
Coggins, MB
Solomon, V
Goldberg, AL
Brand, SJ
Elliott, PJ
机构
[1] ProScript, Cambridge, MA 02139 USA
[2] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 1999年 / 277卷 / 02期
关键词
colon-26; E2(14K); lactacystin; muscle weight loss; proteosome inhibitors; protein metabolism;
D O I
10.1152/ajpendo.1999.277.2.E332
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A new model of cachexia is described in which muscle protein metabolism related to the ubiquitin-proteasome pathway was investigated. Cloning of the colon-26 tumor produced a cell line, termed R-1, which induced cytokine (noninterleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha)-independent cachexia. Implantation of R-1 cells in mice elicited significant (20-30%) weight loss and decreased blood glucose by 70%, and adipose tissue levels declined by 95% and muscle weights decreased by 20-25%. Food intake was unaffected. The decrease in muscle weight reflected a decline in insoluble, but not soluble, muscle protein that was associated with a significant increase in net protein degradation. The rate of ubiquitin conjugation of proteins was significantly elevated in muscles of cachectic mice. Furthermore, the proteasome inhibitor lactacystin blocked the increase in protein breakdown but had no significant effect on proteolysis. Several markers of the ubiquitin-proteasome pathway, E2(14k) mRNA and E214k protein and ubiquitin-protein conjugates, were not elevated. Future investigations with this new model should gain further insights into the mechanisms of cachexia and provide a background to evaluate novel and more efficacious therapies.
引用
收藏
页码:E332 / E341
页数:10
相关论文
共 63 条
[1]   Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? [J].
Andreyev, HJN ;
Norman, AR ;
Oates, J ;
Cunningham, D .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (04) :503-509
[2]  
Auclair D, 1997, AM J PHYSIOL-CELL PH, V272, pC1007
[3]  
BIBBY MC, 1987, J NATL CANCER I, V78, P539
[4]   CELLULAR IMMUNITY IN SEMISTARVED STATES IN HOSPITALIZED ADULTS [J].
BISTRIAN, BR ;
BLACKBURN, GL ;
SCRIMSHAW, NS ;
FLATT, JP .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1975, 28 (10) :1148-1155
[5]   SYNTHESIS OF A FLUORESCENT DERIVATIZING REAGENT, 6-AMINOQUINOLYL-N-HYDROXYSUCCINIMIDYL CARBAMATE, AND ITS APPLICATION FOR THE ANALYSIS OF HYDROLYSATE AMINO-ACIDS VIA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
COHEN, SA ;
MICHAUD, DP .
ANALYTICAL BIOCHEMISTRY, 1993, 211 (02) :279-287
[6]  
CORBETT TH, 1975, CANCER RES, V35, P2434
[7]   TUMOR-NECROSIS-FACTOR-ALPHA MEDIATES CHANGES IN TISSUE PROTEIN-TURNOVER IN A RAT CANCER CACHEXIA MODEL [J].
COSTELLI, P ;
CARBO, N ;
TESSITORE, L ;
BAGBY, GJ ;
LOPEZSORIANO, FJ ;
ARGILES, JM ;
BACCINO, FM .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2783-2789
[8]   EFFECT OF FISH-OIL ON CANCER CACHEXIA AND HOST LIVER-METABOLISM IN RATS WITH PROSTATE TUMORS [J].
DAGNELIE, PC ;
BELL, JD ;
WILLIAMS, SCR ;
BATES, TE ;
ABEL, PD ;
FOSTER, CS .
LIPIDS, 1994, 29 (03) :195-203
[9]   PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS [J].
DEWYS, WD ;
BEGG, C ;
LAVIN, PT ;
BAND, PR ;
BENNETT, JM ;
BERTINO, JR ;
COHEN, MH ;
DOUGLASS, HO ;
ENGSTROM, PF ;
EZDINLI, EZ ;
HORTON, J ;
JOHNSON, GJ ;
MOERTEL, CG ;
OKEN, MM ;
PERLIA, C ;
ROSENBAUM, C ;
SILVERSTEIN, MN ;
SKEEL, RT .
AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) :491-497
[10]  
EARNEST DL, 1990, SEMIN ARTHRITIS RHEU, V19, P6